On October 7, 2020, according to the World Health Organization (WHO), the number of confirmed cases and the corresponding deaths were 35,537,491 and 1,042,798, respectively. Subsequently, the corresponding disease was named coronavirus disease 2019 (COVID-19). There is a need for modification of current protocols and standing orders to provide better care for COVID-19 patients presenting with neurological symptoms.Ī new strain of coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in patients with pneumonia in Wuhan, China, in December 2019. SummaryĬNS manifestations associated with COVID-19 should be considered in clinical practice. Recent FindingsĪ broad spectrum of the CNS manifestations including headache, impaired consciousness, delirium, loss of smell and taste, encephalitis, seizures, strokes, myelitis, acute disseminated encephalomyelitis, neurogenic respiratory failure, encephalopathy, silent hypoxemia, generalized myoclonus, neuroleptic malignant syndrome and Kawasaki syndrome has been reported in patients with COVID-19. In this review, we provide an account of the COVID-19 central nervous system (CNS) manifestations. There is accumulating evidence to suggest that SARS-CoV-2 can target the nervous system.
COVID-19 has a wide range of respiratory symptoms from mild to severe and affects several other organs, increasing the complexity of the treatment. The disease arises from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that binds to angiotensin-converting enzyme 2 (ACE2) receptors on host cells for its internalization. Coronavirus disease 2019 (COVID-19) has become a global health crisis of our time.
0 kommentar(er)
